Publication Date
8-7-2023
Journal
Cell & Bioscience
DOI
10.1186/s13578-023-01091-7
PMID
37550777
PMCID
PMC10408233
PubMedCentral® Posted Date
8-7-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Serotonin, 5-HT, Dorsal Raphe Nucleus, Obesity, Appetite, Weight-loss
Abstract
The prevalence of obesity is rapidly increasing worldwide, while the development of effective obesity therapies lags behind. Although new therapeutic targets to alleviate obesity are identified every day, and drug efficacy is improving, adverse side effects and increased health risks remain serious issues facing the weight-loss industry. Serotonin, also known as 5-HT, has been extensively studied in relation to appetite reduction and weight loss. As a result, dozens of upstream and downstream neural targets of 5-HT have been identified, revealing a multitude of neural circuits involved in mediating the anorexigenic effect of 5-HT. Despite the rise and fall of several 5-HT therapeutics in recent decades, the future of 5-HT as a therapeutic target for weight-loss therapy looks promising. This review focuses on the history of serotonin, the state of current central serotonin research, previous serotonergic therapies, and the future of serotonin for treating individuals with obesity.
Included in
Biochemical Phenomena, Metabolism, and Nutrition Commons, Community Health and Preventive Medicine Commons, Dietetics and Clinical Nutrition Commons, Endocrinology, Diabetes, and Metabolism Commons, Neurosciences Commons, Nutrition Commons, Pediatrics Commons